Healthcare Sector — Q4 FY24 Earnings Overview
3 companies reported. 2 bullish, 1 neutral, 0 bearish.
Average revenue growth: 11.7%
Sector sentiment: bullish
Aggregate revenue: ₹22,920 Cr
Average margin: 15.6%
Company Results
| Company | Revenue | YoY | Margin | Sentiment |
|---|---|---|---|---|
| Sunpharma | ₹11,813 Cr | +10.1% | 25.3% | neutral medium |
| Cipla | ₹6,163 Cr | +10% | 21.4% | bullish high |
| Apollohosp | ₹4,944 Cr | +15% | — | bullish high |
Key sector risks this quarter
Sunpharma · high
OAI status and 483 observations at Mohali and Dadra facilities could impact US generic launches and revenue.
Cipla · highPatalganga received six 483 observations and Kurkumbh one; official classification awaited, potentially delaying product approvals.
Sunpharma · mediumHigher R&D spend (8-10% of sales) and deuruxolitinib launch costs may compress EBITDA margins in FY25.
Sunpharma · mediumStelara biosimilar entry next year could impact Ilumya pricing and market share in the US psoriasis market.
Apollohosp · mediumFour new hospitals with 1,500 beds to be operationalized by calendar 2025-26; initial costs could pressure margins.